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The transplantation of stem cells from a matched unrelated donor (MUD) or a haploidentical mismatched
related donor (MMRD) is a widely used variant of curative treatment for patients with primary immunode-
ﬁciency (PID). Currently, different strategies are used to reduce the risk of post-transplant complications and
enhance immune reconstitution. We report the preliminary results of MUD and MMRD transplantation with
TCRab/CD19 depletion in patients with PID (trial registered at www.clinicaltrials.gov as NCT02327351). Thirty-
seven PID patients (median age, 2.6 years; range, .2 to 17) were transplanted from MUDs (n ¼ 27) or hap-
loidentical MMRDs (n ¼ 10) after TCRabþ/CD19þ graft depletion. The median numbers of CD34þ and TCRabþ
cells in the graft were 11.7  106/kg and 10.6  103/kg, respectively. Acute graft-versus-host disease (GVHD)
was observed in 8 patients (22%), without a statistically signiﬁcant difference between MUDs and MMRDs; 7 of
these patients had grade II acute GVHD and responded to ﬁrst-line therapy, whereas 1 patient had grade IV
acute GVHD with transformation to extensive chronic GVHD. Primary and secondary graft failure (non-
engraftment or rejection) was observed in 10 patients (27%), 9 of whomwere treated with 1 alkylating agent in
the conditioning regimen. All these patients were successfully retransplanted with different rescue protocols.
Preliminary data on immune reconstitutionwere very encouraging. Most patients had signiﬁcant numbers of T
lymphocytes detected on the ﬁrst assessment (day þ30) and more than 500 T cells/mL, on day þ120. Based on
our preliminary data, no signiﬁcant difference was seen between MMRD and MUD hematopoietic stem cell
transplantation (HSCT). With a median follow-up period of 15 months, the cumulative probabilities of overall
patient survival and transplant-related mortality were 96.7% and 3.3%, respectively. Based on the results, the
ability to control the main post-transplant complications and the immune reconstitution rates are the main
factors leading to successful outcome in patients with PID after TCRabþ-depleted HSCT.
 2015 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
For several decades now, hematopoietic stem cell trans-
plantation (HSCT) has been the main curative treatment
modality for patients with various primary immunodeﬁ-
ciency (PID) syndromes. Because only a small proportion of
patients with inherited diseases have an HLA-identicaledgments on page 1962.
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sevier Inc. on behalf of American Society for Blrelated donor, transplantation of stem cells from a matched
unrelated donor (MUD) or a haploidentical mismatched
related donor (MMRD) is a widely used variant of HSCT. The
most serious complications of HSCT from an alternative
donor are acute and chronic graft-versus-host disease
(GVHD) and graft failure for haploidentical donor HSCT
(especially for non-SCID PID), which often leads to prolonged
morbidity and late immune reconstitution with secondary
immunodeﬁciency. Despite the fact that the frequency of
acute GVHD after alternative donor HSCT does not exceed
20%, the incidence rate of life-threatening acute GVHD
(higher than grade II) is more than 8% to 10% [1,2].ood and Marrow Transplantation.
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tion or positive CD34þ selection is a routine method of GVHD
prevention after haploidentical HSCT. However, this method
leads to prolonged immunoincompetence in patients,
resulting in a high incidence of infections and associated
complications, which affect the outcome of HSCT [3].
TCRab depletion coupled with CD19 graft depletion is a
promising technology, potentially capable of reducing the
incidence of acute and chronic GVHD and enhancing im-
mune reconstitution. There are encouraging reports of a
small series of patients with hematologic malignancies and
nonmalignant disorders who were transplanted with stem
cells from MMRDs by using this approach [4-7]. T cells with
ab-chain TCRs are the major inducers of GVHD, and their
elimination from the graft decreases the frequency of this
complication [7,8]. At the same time, T cells with gd-chain
TCRs combine conventional adaptive features with rapid
innate-like responses that place them in the initiation phase
of immunoreactions [9]. These cells are able to recognize
target cells through MHC-independent mechanisms
involving activating receptors (eg, gd TCR, NKG2D, TLRs, and
DNAM-1), resulting in the rapid production of cytokines
(IFN-g and tumor necrosis factor-a) and a cytotoxic response
[9]. Because their immunologic response does not depend on
MHC, gd T cells, in contrast to ab T cells, play a limited role in
the development of GVHD, the pathogenesis of which is
based on HLA alloreactivity. Conversely, gd T cells have high
activity against intra- and extracellular pathogens [10-13].
Not surprisingly, the existing experience with TCRab-
depleted transplants shows early immune reconstitution and
a low incidence of GVHD after haploidentical HSCT [5-7].
More recently, a case series of TCRab-depleted hap-
loidentical transplantation in patients with PID was reported
from different clinical groups [4,7]. Here, we share our pre-
liminary results on TCRab/CD19-depleted transplantation
from MMRDs and MUDs in patients with PID.
METHODS
This trial was registered at www.clinicaltrials.gov as a prospective,
interventional, single-group, open-label study (NCT02327351).
Patients
Thirty-seven PID patients, with amedian age of 2.6 years (range, .2 to 17),
were transplanted between July 2012 and September 2014. The diagnosis of
PIDwasmade based on the European Society for Immunodeﬁciencies criteria
(http://esid.org/Working-Parties/Registry/Diagnosis-criteria) and in most
cases was conﬁrmed genetically.
Transplantation Characteristics
The source of stem cells was peripheral blood from a MUD (n ¼ 27) or
MMRD (n ¼ 10). All grafts were TCRabþ/CD19þ depleted before trans-
plantation by using an immunomagnetic method in accordance with the
manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, Germany).
Reduced-intensity conditioning, consisting of treosulfan (36 to 42 g/m2
total dose; days 5, 4, and 3) and ﬂudarabine (150 mg/m2 total dose;
days6,5,4,3, and2) was used as the primary conditioning regimen.
Thirty-ﬁve patients received serotherapywith antithymocyte globulin (ATG;
rabbit) (5 mg/kg; days 5 and 4), and 2 patients were treated with
alemtuzumab (1 mg/kg; days 9 and 8). Eight patients with a high risk of
graft rejection (eg, those with severe congenital neutropenia [SCN], chronic
granulomatous disease, or hyper-IgM syndrome) additionally received
melphalan (140mg/m2; day2). On day1,14 patients received 100mg/m2
rituximab to reduce the risk of Epstein-Barr viruserelated post-transplant
lymphoproliferative disease. One patient with SCID was transplanted
without conditioning due to infectious complications and severe organ
failure (Table 1).
GVHD prophylaxis consisted of tacrolimus (T steady state ¼ 8 to 12 ng/
mL; from days 1 to þ60) and a short course of methotrexate (5 mg/m2;
days þ1, þ3, and þ6) in 34 patients, tacrolimus and mycophenolate mofetil
in 2 patients, and cyclosporine and methotrexate (5 mg/m2; days þ1, þ3,and þ6) in 1 patient. GVHD was graded according to the standard criteria.
The major endpoints of the study were grades II to IV acute GVHD, primary
and secondary graft failure, viral infection, immune reconstitution, and
transplant-related mortality.
Statistical Analysis
Data as of December 31, 2014 were analyzed. Patients were censored at
time of death and last follow-up. The probabilities of overall survival and
event-free survival were estimated by the Kaplan-Meier product limit
method and were expressed as percentage  standard error. The events
(event-free survival) were analyzed as death or primary/secondary graft
failure after ﬁrst HSCT. The probabilities of acute and chronic GVHD, graft
failure, cytomegalovirus (CMV), and transplant-related mortality were
calculated as cumulative incidence curves  standard error to adjust the
analysis for competing risks. Statistical analysis was done by using the
XLSTAT 2015 software from Addinsoft, Paris, France.
RESULTS
The median follow-up period was 392 days (range, 120 to
876). Patients were transplanted with a median of 11.7 106/
kg (range, 5.9 to 21.3) CD34þ cells, and themedian number of
TCRabþ cells in the graft was 10.6  103/kg (range, .8 to 368).
Neutrophil engraftment occurred in 35 of 37 patients on days
11 to 28 after transplantation (median, 16 days); the cumu-
lative incidence was 94.6% (95% conﬁdence interval [CI],
87.6% to 100%).
Grades II to IV acute GVHD occurred in only 8 cases
(25.4%; 95% CI, 13.8% to 46.7%). Importantly, 7 of these 8
cases presented clinical manifestations of grade II acute
GVHD (2 with skin and intestinal GVHD and 6 with skin
GVHD only) and responded to ﬁrst-line therapy. One patient
who underwent HSCT without conditioning developed
grade IV acute GVHD; later, this patient developed re-
fractory extensive chronic GVHD and partially responded to
mesenchymal stem cell therapy and extracorporeal photo-
pheresis. No patients had grade III GVHD. Therefore, the
cumulative probabilities of grades II and IV acute GVHD
were 21.5% (95% CI, 11.1% to 41.7%) and 2.8% (95% CI, .4% to
19.2%), respectively (P ¼ .03) (Figure 1A). The cumulative
probabilities of acute GVHD after haploidentical HSCT
(33.3%; 95% CI, 12.9% to 85.9%) and unrelated HSCT (20.2%;
95% CI, 9.2% to 44.3%) were not statistically different
(P ¼ .41) (Figure 1B).
Early toxicity, such as treosulfan-related skin rash and
mucositis, was limited to a few observations and was mild in
all cases. The most signiﬁcant noninfectious complications
were BCG (Bacillus CalmetteeGuérin)-associated hemo-
phagocytic lymphohistiocytosis in a patient with SCID and
hemorrhagic cystitis in a patient with WHIM (Warts, Hypo-
gammaglobulinemia, Infections, and Myelokathexis) syn-
drome. To date, no patient has developed Epstein-Barr
viruserelated post-transplant lymphoproliferative disease.
Viral infections are a well-known complication of
T celledepleted HSCT. In our group, CMV reactivation
occurred in 16 of 37 patients; the cumulative incidence was
46% (95% CI, 32.1% to 66.5%), with no signiﬁcant difference
between MMRD and MUD groups (P ¼ .86) (Figure 2A,B). We
observed 5 cases of CMV disease (4 patients had CMV cho-
rioretinitis and 1 had CMV-associated pneumonia). It should
be noted that CMV pneumonia was observed in 1 patient
with SCN after a second HSCT was carried out because of
initial graft failure.
Primary and secondary graft failure (nonengraftment or
rejection) was observed in 10 cases (27%): 2 patients with
SCN failed to engraft and 8 patients rejected the graft within
31 to 241 days (median time to rejection, 112 days) (Table 1,
Figure 3). Overall, the cumulative probability of developing
Table 1
Patient Characteristics and HSCT Features
Patient
No.
Diagnosis Sex Age
(yr)
Type of Donor
(Compatibility)
Conditioning Regimen WBC
Engraftment
(days)
GVHD Rejection
(days)
Second
HSCT
Outcome
(Alive-Days
or Death)
Acute
Grades II-IV
Chronic
1 HIGM M 2 MUD (10/10) Treo, Flu, ATG þ15 d d þ159 Yes þ876
2 SCID M .2 MMRD Treo, Flu, Alem þ15 d d d d þ840
3 CGD M 5 MUD (10/10) Treo, Flu, ATG þ16 d d þ140 Yes þ776
4 WAS M .9 MUD (10/10) Treo, Flu, ATG þ13 II (s, gi) d d d þ806
5 CID F 1 MUD (10/10) Treo, Flu, ATG þ14 d d d d þ771
6 WAS M 6 MUD (10/10) Treo, Flu, ATG þ16 II (s, gi) d d d þ679
7 WAS M 5 MUD (10/10) Treo, Flu, ATG þ13 II (s) d d d þ630
8 WHIM F 3 MUD (10/10) Treo, Flu, ATG þ15 d d d d þ621
9 SCID M .6 MMRD Treo, Flu, ATG þ14 d d þ238 Yes þ587
10 WAS M 1 MMRD Treo, Flu, ATG þ13 II (s) Lim. d d þ531
11 HLH F 2 MMRD Treo, Flu, ATG þ20 d d d d þ503
12 WAS M 2 MUD (10/10) Treo, Flu, ATG þ21 d d d d þ441
13 HLH M 11 MUD (10/10) Treo, Flu, ATG þ18 d d d d þ392
14 HLH M 15 MUD (10/10) Treo, Flu, ATG þ16 d d d d þ412
15 CID M 4 MUD (10/10) Treo, Flu, ATG þ19 d d þ75 Yes þ463
16 SCN M 9 MUD (10/10) Treo, Flu, ATG No d d d Yes Death þ141
17 SCID M 1 MMRD Treo, Flu, ATG þ20 d d d d þ784
18 STAT1 M 6 MUD (10/10) Treo, Flu, ATG þ17 d d þ28 Yes þ291
19 WAS M 2 MUD (10/10) Treo, Flu, ATG þ17 d d þ183 Yes þ320
20 HLH F 6 MUD (10/10) Treo, Flu, ATG þ19 d d d d þ699
21 NBS F 17 MUD (10/10) Bu, Cy, Flu, ATG þ20 d d d d þ412
22 NBS M 5 MUD (10/10) Bu, Cy, Flu, ATG þ16 d d d d Death þ81
23 SCN M 1 MUD (10/10) Treo, Flu, Melph, ATG þ13 d d d d þ258
24 CGD M 3 MUD (9/10) Treo, Flu, Melph, ATG þ13 d d d d þ245
25 SCID (OS) F .3 MMRD Treo, Flu, Alem þ15 II (s) d d d þ187
26 HIGM M 4 MUD (10/10) Treo, Flu, Melph, ATG þ12 II (s) d d d þ197
27 HIGM M 1 MUD (10/10) Treo, Flu, Melph, ATG þ11 d d d d þ231
28 SCN M 1 MMRD Treo, Flu, Melph, ATG No d d d Yes þ250
29 WAS M 1 MMRD Treo, Flu, ATG þ17 d d d d þ139
30 SCID M 2 MMRD No conditioning þ IV (s, gi, l) Ext. d d þ224
31 WAS M 2 MUD (9/10) Treo, Flu, ATG þ28 d d d d þ162
32 CHH F 3 MUD (10/10) Flu, Melph, ATG þ25 d d þ35 yes þ134
33 CHS M 0.6 MUD (10/10) Treo, Flu, Melph, ATG þ15 II (s) d d d þ105
34 CID M 3 MUD (10/10) Treo, Flu, ATG þ12 d d d d þ103
35 IPEX M 11 MUD (10/10) Treo, Flu, Melph, ATG þ14 d d d d þ96
36 HLH M 2 MMRD Treo, Flu, ATG þ12 d d þ34 Yes þ111
37 XLP M 11 MUD (10/10) Treo, Flu, Melph, ATG þ13 d d d d þ405
HIGM indicates hyper-IgM syndrome; Treo, treosulfan; Flu, ﬂudarabine; Alem, alemtuzumab; CGD, chronic granulomatous disease; WAS, Wiskott-Aldrich
syndrome; s, skin; gi, gastrointestinal tract; CID, combined immunodeﬁciency, undeﬁned; Lim., Limited; HLH, hemophagocytic lymphohistiocytosis; STAT1,
Signal transducer and activator of transcription 1 mutation; NBS, Nijmegen breakage syndrome; Bu, busulfan; Cy, cyclophosphamide; Melph, melphalan; OS,
Omenn syndrome; l, liver; Ext., extensive; CHH, cartilage hair hypoplasia; CHS, Chediak Higashi syndrome; IPEX, immune dysregulation, polyendocrinopathy,
enteropathy, X-linked inheritance; XLP, X-linked lymphoproliferative syndrome.
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without a signiﬁcant difference between haploidentical
(36%; 95% CI, 13% to 93%) and unrelated (28%; 95% CI, 15% to
52%) (P ¼ .81) HSCT groups (Figure 3A).Figure 1. Cumulative incidence of grades II and IV acute GVHD (A) and probability of a
acute GVHD. CI indicates cumulative incidence.Importantly, 9 of 10 patients with primary or secondary
graft failure were transplanted with reduced-intensity con-
ditioning regimens consisting of 1 alkylating agent (treo-
sulfan, ﬂudarabine, ATG or ﬂudarabine, melphalan, ATG)cute GVHD after haploidentical and unrelated HSCT (B). No patient had grade III
Figure 2. Cumulative probability of CMV reactivation for all patients (A) and CMV reactivation in haploidentical and unrelated HSCT recipients (B).
D. Balashov et al. / Biol Blood Marrow Transplant 21 (2015) 1955e19621958(36.7%; 95% CI, 21% to 60.9%). Only 1 patient failed to engraft
after a treosulfan/melphalan-based conditioning regimen
(treosulfan, ﬂudarabine, melphalan, ATG) (10%; 95% CI, 16% to
64%) and haploidentical HSCT (Figure 3B). In this patient, anti-
HLA antibodies, speciﬁc to both parents, were detected. All
patients with rejected and nonengrafted transplants were
retransplanted according to various rescue protocols (Table 2).
The evaluation of immune reconstitution was one of the
most important objectives of our study. The kinetics
observed in the study group, including the restoration of the
fraction of naive T lymphocytes, were very encouraging
(Figure 4). Most patients had signiﬁcant numbers of T lym-
phocytes detected at the ﬁrst assessment (day þ30) and
more than 500 T cells/mL on day þ120. Signiﬁcant numbers
of B lymphocytes (>200/mL on average) were detected in
most patients on day þ120. Longer follow-up is needed to
compare the characteristics of immune reconstitution be-
tween MUD and MMRD; however, the combined data
showed excellent reconstitution results (Figure 5).Figure 3. Probability of graft dysfunction (primary or secondary graft failure). (A) Gra
containing 1 alkylating agent (RIC). (B) Comparison of graft failure in groups with 1
reduced-intensity conditioning; Mel, melphalan.The cumulative incidence of event-free survival was
67.7% (Figure 6A). Despite the high incidence of primary
and secondary graft failure after primary HSCT with 1
alkylating agent in the conditioning regimen, 8 of 10 pa-
tients were retransplanted with successful outcomes
(Table 2). Therefore, the probability of overall survival for
patients in this study was 96.7% (95% CI, 86% to 100%)
(Figure 6B). Currently, 35 of 37 patients studied are alive,
and 34 of them are disease-free. One patient (with Nijme-
gen breakage syndrome) died from a relapse of non-
Hodgkin lymphoma 81 days post-HSCT. The death of the
second patient with SCNwas directly related to HSCT. In this
patient, a case of nonengraftment after the ﬁrst HSCT, a
prolonged period of aplasia, and reactivation of CMV with
the development of severe CMV disease after a second HSCT
were observed. Eventually, the patient succumbed to CMV
pneumonia. Thus, the cumulative probability of transplant-
related mortality in our study was only 3.3% (95% CI, .5% to
22%).ft failure after haploidentical and unrelated HSCT with conditioning regimens
and 2 alkylating agents in the conditioning regimen (RICþMel). RIC indicates
Table 2
Second HSCT Characteristics after Primary or Secondary Graft Failure
Patient No. Diagnosis Second HSCT Outcome (Day after Second HSCT)
Conditioning Graft Manipulation Engraftment
1 HIGM TLI 6 Gr
Flu 150 mg/m2
Melph 140 mg/m2
ATG (rabbit) 5.0 mg/kg
MUD/PBSC
TCRab/CD19þ depleted
þ Alive
3 CGD Bu 16 mg/kg
Flu 150 mg/m2
Alem 1.0 mg/kg
MUD/BM
Nonmanipulated
þ Alive
9 SCID TLI 6 Gr
Flu 150 mg/m2
Melph 140 mg/m2
ATG (rabbit) 5.0 mg/kg
MMRD/PBSC
TCRab/CD19þ depleted
þ Alive
15 CID TLI 6 Gr
Flu 150 mg/m2
Melph 140 mg/m2
ATG (rabbit) 5.0 mg/kg
MMRD/PBSC
TCRab/CD19þ depleted
þ Alive
16 SCN TLI 6 Gr
Flu 150 mg/m2
Melph 140 mg/m2
ATG (rabbit) 5.0 mg/kg
MMRD/PBSC
TCRab/CD19þ depleted
No Death þ42
18 STAT1 TLI 6 Gr
Flu 150 mg/m2
Cy 120 mg/kg
ATG (rabbit) 5.0 mg/kg
MMRD/PBSC
TCRab/CD19þ depleted
þ Alive
19 WAS TLI 6 Gr
Flu 150 mg/m2
Melph 140 mg/m2
Alem 1.0 mg/kg
MUD/BM
Nonmanipulated
þ Rejection on day þ94
Alive
28 SCN TLI 6 Gr
Flu 150 mg/m2
Thiotepa 10 mg/kg
ATG (rabbit) 5.0 mg/kg
MMRD/BM
Cy þ3, þ4
No Alive
32 CHH Trfp 42 g/m2
Flu 150 mg/m2
Thiotepa 10 mg/kg
ATG (rabbit) 5.0 mg/kg
MUD/PBSC
Cy þ3, þ4
þ Alive
36 HLH Trfp 42 g/m2
Flu 150 mg/m2
Cy 30 mg/kg
MUD/BM
Cy þ3, þ4
þ Alive
TLI indicates total lymphoid irradiation; PBSC, peripheral blood stem cells; BM, bone marrow.
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TCRabþ/CD19þ graft depletion is a relatively new tech-
nology, originally used primarily for the preparation of
MMRD transplants. However, the preliminary results of
several research groups have been very promising and thus
have led to the expanding range of indications and wider use
of the technology. Hence, we carried out an interventional,
single-group, open-label study that included patients with
various PID syndromes who underwent HSCT from MMRDs
or MUDs in our institution between 2012 and 2014. The aim
of the study was to investigate transplant-related mortality,
the risks and severity of GVHD, and the rate of immune
reconstitution after TCRabþ/CD19þ MUD and MMRD HSCT.
Themain objectivewas to assess the feasibility of the TCRabþ
graft depletion technology for HSCT in PID patients, as
determined by the ﬁnal outcome of HSCT.
One of the main goals of the trial was the reduction of
toxic complications related to the conditioning regimen. For
most patients conditioning was based on treosulfan and
ﬂudarabine. Two patients with Nijmegen breakage syn-
drome were conditioned with low-dose busulfan and
cyclophosphamide, and only in 1 case (a patient with SCID)
was HSCT performed without conditioning; the latter was
due to the poor performance status of the patient, which was
associated with life-threatening infectious complications. By
using this approach, we observed good tolerability of theHSCT procedure, a good rate of engraftment, and absence of
serious toxic complications in all transplanted patients. The
incidence of acute GVHDwasmoderate (25.4% for grades II to
IV GVHD and 21.5% % for grade II GVHD) and, in most cases,
did not require long-term or second-line therapy. Our results
are somewhat different from those of Bertaina et al. [7], who
reported an even lower incidence of acute GVHD (13%) in a
group of 23 nonmalignant patients who were transplanted
without GVHD prophylaxis. However, the 22.2% overall
probability of GVHD found in our study is higher than the
published results for unmanipulated HSCT. For example,
Grunebaum et al. [14] reported a 73% probability of GVHD in
a group of SCID patients who underwent unmanipulated
HSCT from fully MUDs; in 3 of 41 patients, GVHD was the
cause of death. In contrast, GVHD was not a major issue in
our study group. Only 1 patient with SCID, transplanted
without prior conditioning, suffered from grade IV severe
acute GVHD. We believe the absence of serotherapy was the
cause of such severe complications in this patient, and this
should be taken into account in future unconditioned
transplants.
Viral infections that complicate HSCT continued to be a
problem in our group of patients. CMV reactivation occurred
in 49.6% of MUD and 40% of MMRD HSCT patients; however,
the frequency of CMV infection after HSCT was still lower
compared with historical control subjects in the same center
Figure 4. Restoration of lymphocytes subpopulations after TCRabþ/CD19þ-depleted HSCT: (A) CD3þ cells; (B) ab T cells; (C) naive T cells; (D) B cells.
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reactivation: MUDs, 60%; MMRDs, 66%). Life-threatening
CMV disease (pneumonia) occurred in only 1 patient in our
study. Among the factors that contributed to the reduction in
the CMV infection rate after HSCT with TCRabþ/CD19þ
depletion were the low frequency and severity of acute
GVHD and, as a consequence, the absence of long-term
immunosuppressive therapy [15].
The main problem in our study was the high frequency of
primary or secondary graft failure (29.5%). However, this
occurred mostly in patients with an initial high risk of
transplant failure, such as those with SCN, chronic granulo-
matous disease, or hyper-IgM syndrome. Furthermore, it
should be noted that 9 of 10 patients with primary non-
engraftment/rejection were conditioned with only 1 alky-
lating agent. More likely, when using conditioning regimens
containing only 1 alkylating agent, the probability of the
existing hosts’ cells having powerful immune potential is
higher. Thereby, in the presence of donors’ much lower
T cellemediated alloreactivity after TCRabþ graft depletion,
patients’ T cells trigger the host-versus-graft effect, which
ﬁnally leads to the rejection. The only patient with graft
rejection after treosulfan/melphalan-containing condition-
ing was diagnosed with high levels of speciﬁc anti-HLAantibodies in the HSC donor cells, which undoubtedly
contributed to the transplant rejection.
Although the general tendency in the ﬁeld of HSCT has
been shifting toward lower-intensity conditioning regimens
that are associated with a reduction of post-transplant
toxicity, such regimens are well known to be risk factors
for transplantmalfunction [16]. In our study themodiﬁcation
of the pretransplant conditioning for patients with a high
risk of graft failure by the addition of a second alkylating
agent (melphalan) led to improved engraftment without any
increase in the levels of post-transplant toxicity.
Immune reconstitution after HSCT is one of the most
important characteristics that determine the success of
treatment. Handgretinger [5] showed that TCRabþ deple-
tion technology guarantees a fast immune reconstitution.
In our study the kinetics of immune reconstitution pa-
rameters, including naive T cell counts, were consistent
with our expectations and the reports of other researchers
[4,7]. Based on our preliminary data, there was no signif-
icant difference between MMRD and MUD HSCT. This
result sheds new light on MMRD HSCT in PID patients with
severe infectious complications for whom a fast immune
reconstitution is most beneﬁcial. Although the number of
patients in our study is too small for us to draw ﬁnal
Figure 5. Flow cytometry results in a patient with SCID after haploidentical TCRabþ/CD19þ-depleted HSCT. (A and B) CD3þ cells on day þ60 (A) and day þ120 (B)
after HSCT. (C and D) Naive T cells on day þ60 (C) and day þ120 (D) after HSCT.
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HSCT from MMRDs, compared with other sources of stem
cells, without a signiﬁcant increase in HSCT-related
complications.Figure 6. Probability of (A) event-free survival (EFS) and (B) cumulative incidence ofTo date, the study is still ongoing. However, based on the
presented results, we conclude that the ability to control the
main post-transplant complications and immune reconsti-
tution rates are the main factors leading to successfuloverall survival (OS) in patients with PIDs after TCRabþ/CD19þ-depleted HSCT.
D. Balashov et al. / Biol Blood Marrow Transplant 21 (2015) 1955e19621962outcome in patients with PID after TCRabþ/CD19þ-depleted
HSCT.
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